欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2023, Vol. 28 ›› Issue (6): 671-675.doi: 10.12092/j.issn.1009-2501.2023.06.01

• 药物治疗学 • 上一篇    下一篇

他汀类药物治疗伴高脂血症偏头痛患者的临床疗效分析

赵 璐1,李付勇2,温滨红1,李道伟3   

  1. 1辽宁省人民医院内分泌科,2神经外科,3影像科,沈阳  110016,辽宁
  • 收稿日期:2023-03-29 修回日期:2023-05-20 出版日期:2023-06-26 发布日期:2023-07-12
  • 通讯作者: 李付勇,男,博士研究生,主任医师,研究方向:偏头痛及脑血管病的治疗。 E-mail:lifuyongvip@126.com
  • 作者简介:赵璐,女,硕士,副主任医师,研究方向:内分泌与代谢病。 E-mail:59040415@qq.com
  • 基金资助:
    辽宁省自然基金项目(2021-MS-059);辽宁“百千万人才工程”培养经费资助项目B43

Effects of stains on hyperlipidemia and pain relieve of patients with chronic migraine 

ZHAO Lu1, LI Fuyong2, WEN Binhong1, LI Daowei3   

  1. 1Department of Endocrinology, 2Department of Neurosurgery, 3Department of Imaging, The People's Hospital of Liaoning Province, Shenyang 110016, Liaoning, China 
  • Received:2023-03-29 Revised:2023-05-20 Online:2023-06-26 Published:2023-07-12

摘要:

目的:探讨他汀类药物治疗伴高脂血症偏头痛患者的临床疗效。方法:回顾性分析2016年9月至2021年8月于我院诊断治疗的118例高脂血症同时患偏头痛患者的临床资料,根据高脂血症情况及既往心脑血管病史,分别给予阿托伐他汀20 mg(A组)、40 mg(B组)及瑞舒伐他汀10 mg(C组)、20 mg(D组)治疗,对比血脂指标改善情况,评价用药后3个月平均视觉疼痛分析量表(visual analongue scale,VAS),头痛发作频率,与用药前3个月内同一指标对比。结果:四组血脂控制总有效率满意,分别为91.7%、94.1%、88.2%及92.9%,高剂量他汀组控制率略高(B组vs. A组,D组vs. C组)。治疗后,四组患者偏头痛均有不同程度的减轻,其中A组为最低组,有效率为36.1%,D组为最高组,有效率为53.6%,其中高剂量他汀组(B组和D组)疼痛平均VAS、发作频率疼痛缓解更明显。用药后,疼痛发作VAS评分减少50%及发作频率降低50%各组间比较差异无统计学意义(P>0.05)。结论:应用他汀类药物治疗伴高脂血症偏头痛的患者,高脂血症控制满意,他汀类别无明显差异;伴有的偏头痛症状可得到不同程度的缓解,部分患者临床疗效可靠。

关键词: 他汀类药物, 高脂血症, 偏头痛, 疼痛缓解

Abstract:

AIM: To investigate the clinical efficacy of statins in the treatment of patients with migraine and hyperlipidemia. METHODS: A retrospective analysis was performed on the clinical data of 118 patients with hyperlipidemia and migraine diagnosed and treated in our hospital from September 9, 2016 to August 2021. According to hyperlipidemia and previous cardio-cerebral vascular disease history, Atorvastatin and Rosuvastatin were given different doses respectively, and the improvement of blood lipid index was compared. The average VAS, headache frequency and headache frequency at 3 months after treatment were compared with those before treatment.Comparison of the same indicator within 3 months. RESULTS: The total effective rate of blood lipid control in each group was satisfactory, which was 91.7%, 94.1%, 88.2% and 92.9%, respectively. Group B and Group D had a slightly higher control rate in the high-dose statin group compared with similar groups A and C. After treatment, all four groups of patients had different degrees of migraine reduction, and group A was the lowest group with response rate of 36.1%, and group D was the highest group with response rate of 53.6%. The average VAS of pain in the high-dose statin group was greater and the pain relief was more pronounced. There was no significant statistical difference between the groups in the pain onset of VAS score reduction by 50% and the frequency of attacks by 50%, P>0.05. CONCLUSION: The use of statins in the treatment of patients with hyperlipidemia and migraine has satisfactory control of hyperlipidemia, and there is no significant difference in statin categories. The migraine symptoms associated with them can be relieved to varying degrees, and some patients have reliable clinical effects.

Key words: statins, hyperlipidemia, migraine, pain relief

中图分类号: